PolynovoCALZF 74 Days Payable is 274.09 as of Dec. 2025, which is 2% above its 10-year median of 269.62. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.21 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Polynovo ranks better than 90.94% on this metric.
Polynovo's average Accounts Payable for the
six
months ended in Dec. 2025 was $7.63 Mil. Polynovo's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $5.08 Mil.
Hence, Polynovo's Days Payable for the
six
months ended in Dec. 2025 was 274.09.
The historical rank and industry rank for Polynovo's Days Payable or its related term are showing as below:
CALZF'
s Days Payable Range Over the Past 10 Years
Min: 113.53 Med: 269.62 Max: 468.32
Current: 388.12
During the past 13 years, Polynovo's highest Days Payable was 468.32. The lowest was 113.53. And the median was 269.62.
CALZF's Days Payable is ranked better than 90.94% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs CALZF: 388.12
Polynovo's Days Payable
declined
from Dec. 2024 (1,682.99) to Dec. 2025 (274.09).
It may suggest that Polynovoaccelerated paying its suppliers.
Polynovo Days Payable Related Terms
Polynovo Days Payable Historical Data
* Premium members only.
The historical data trend for Polynovo's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Days Payable distribution charts can be found below:
* The bar in red indicates where Polynovo's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Polynovo's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (CALZF) has a Days Payable of 274.09 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Polynovo and its competitors. This is near median its historical median of 269.62. Over the past decade, Polynovo's Days Payable has ranged from 113.53 to 468.32. According to the industry distribution chart, Polynovo ranks #72 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 9.1%.
Is Polynovo's Days Payable too high?
Polynovo's current Days Payable of 274.09 is near median its 10-year median of 269.62. Over the past 10 years, this metric has ranged from a low of 113.53 to a high of 468.32. The Medical Devices & Instruments industry median Days Payable is 68.07. Polynovo's value of 274.09 is 302.7% above this industry median. Based on the distribution chart, Polynovo ranks #72 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #72 out of 795 companies for Days Payable. This places Polynovo in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Polynovo's value of 274.09 is 302.7% above this benchmark. Historically, Polynovo's own Days Payable has ranged from 113.53 to 468.32 over the past decade. While the company's 10-year median is 269.62 vs. the industry median of 68.07, Polynovo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current Days Payable of 274.09 is 302.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current Days Payable is 274.09, which is near median its own 10-year median of 269.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.21, compared to a current price of $0.62 — trading 71.9% below its estimated fair value. The current Days Payable is 274.09, which is near median its 10-year median of 269.62 and 302.7% above the Medical Devices & Instruments industry median of 68.07. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Polynovo (CALZF), the current Days Payable is 274.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.62 is trading 71.9% below its estimated GF Value™ of $2.21.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
Days Payable: 274.09 (near median its 10-year median of 269.62)
GF Value™: $2.21 vs. price of $0.62 (71.9% below fair value)
Industry Position: 302.7% above the Medical Devices & Instruments median (#72 of 795)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
